The FDA rejected Moderna's mRNA flu vaccine application earlier this year. Said the trial design was flawed. Said Moderna compared its shot against a standard flu vaccine instead of the high-dose version recommended for seniors. The application was dead.
One week later, the FDA approved it anyway.
The man who issued the original rejection was Vinay Prasad, then the FDA's director of the Center for Biologics Evaluation and Research — and a vocal RFK ally who had been applying genuine scrutiny to new vaccine applications. On February 18th, the refusal was reversed under pressure. By April 30th, Prasad was gone from the agency.
Draw your own conclusions about the sequence of events.
The vaccine is called mFLUSIVA, and as of August 5, 2026, it is the first mRNA-based flu shot ever cleared by the FDA — approved for adults 50 and older in two tiers: full approval for ages 50 to 64, and accelerated approval for those 65 and up. Accelerated approval means the confirmatory data doesn't exist yet. Moderna is required to run additional studies over two flu seasons to prove it actually works for the group most likely to die from the flu.
The studies come after the shots go in the arms of seniors. That's how accelerated approval works.
FDA Commissioner Marty Makary characterized the original rejection as "part of a conversation that occurs with all drug makers." That's a creative way to describe a formal refusal followed by a complete reversal in seven days. Most conversations don't end with one side entirely changing its position in under a week. Unless the conversation involved something other than science.
Dr. Brian Hooker, chief medical officer at Children's Health Defense, isn't satisfied with how this went. "I really believe that this technology is just too new," Hooker said. "There has not been the adequate level of study of the implications for, you know, literally everybody. I just feel like the train is leaving the station, and we're not ready yet."
The approval puts HHS Secretary Robert F. Kennedy Jr. in a complicated position. Kennedy has spent years criticizing mRNA technology and his department cancelled $500 million in mRNA vaccine research funding through BARDA — 22 development projects, gone. His own spokesperson offered careful framing: "Secretary Kennedy has been clear that he believes mRNA products warrant heightened scientific scrutiny. That's why this vaccine is entering the market with some of the strongest post-market study commitments FDA has required."
Post-market study commitments. Meaning the scrutiny comes after it's already been approved.
There's also the question of whether most Americans can even get the shot covered by insurance. A federal judge blocked the Advisory Committee on Immunization Practices — ACIP — from convening. Without an ACIP recommendation, federal programs and private insurers won't cover it. The FDA approved it, but the infrastructure to actually deliver it to patients is jammed.
The FDA rejected the application. Then reversed course in a week. The man who made the original call was gone within months. The HHS secretary has called mRNA technology the deadliest vaccine ever made. And the highest-risk age group got accelerated approval — meaning Moderna's confirmatory data arrives after millions of seniors have already gotten the shot.
That's not a regulatory process. That's a regulatory shrug.
